The delivery of a second development candidate to Biogen and the associated $8 million milestone payment is a significant achievement for C4 Therapeutics. This milestone not only strengthens their partnership with Biogen but also provides a financial boost, which is likely to positively influence investor sentiment and drive the stock price up in the short term.